Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentThe current reopening looks different from the pandemic-era boom because investors are being more selective and still writing large checks when conviction is high. The main risks, according to Leerink’s Jack Bannister, are preclinical companies rushing out and issuers pushing valuation too far.
Dr. Priya NandakumarAug 26, 2026
Healthcare InvestmentThe agreement pairs a China-origin immunology asset with U.S. venture backing and a newco structure aimed at ex-China development. For Haisco, it adds another large outbound transaction in a year already marked by deals with Eli Lilly, Nuvectis and AbbVie.
Dr. Priya NandakumarAug 26, 2026
Biopharmaceutical IndustryFoundayo is approved in the U.K. for adults with obesity or who are overweight and have at least one weight-related comorbidity, and it is also indicated for type 2 diabetes. Analysts cited by BioSpace said Lilly may be better positioned outside the U.S. because Foundayo is a small-molecule drug, potentially supporting better margins and more pricing flexibility than a peptide rival.
Dr. Priya NandakumarAug 25, 2026
Regulatory & PolicyAbramson told STAT that the ecosystem should expect clarity on generative AI through future FDA documents. The message is less about immediate rule changes than about the agency moving from general discussion to a defined policy framework for a technology category that developers increasingly need mapped to regulatory expectations.
Dr. Priya NandakumarAug 25, 2026
Biopharmaceutical IndustryTA-ERT could become the first FDA-approved therapy for MPS IIIB if Spruce reaches the regulator on its revised timeline. The latest update matters less as a clinical surprise than as a manufacturing de-risking step for a program whose data were viewed as more settled than its CMC path.
Dr. Priya NandakumarAug 24, 2026Now executive director of The Evidence Collective, Marnik has become a visible vaccine communicator on Instagram, Substack and in public talks. Her story points to a strategic issue in public health communication: strong evidence may be necessary, but sources and messengers still shape whether people hear it.
Dr. Priya NandakumarAug 19, 2026
Biotech InnovationThe Lugano trial tested duravyu against aflibercept in about 400 patients with wet age-related macular degeneration and did not meet its main endpoint on best corrected visual acuity after two years. EyePoint highlighted ad hoc and secondary analyses, while Mizuho called the overall result mixed and shifted attention to the upcoming Lucia readout.
Dr. Priya NandakumarAug 17, 2026
Biopharmaceutical IndustryBioSpace reports that manufacturers including Australia’s BLS Pharmaceuticals and Canada’s Optimi Health are preparing to supply MDMA and psilocybin products into the U.S. as policy support grows. Their opportunity depends not just on clinical progress, but on whether companies can satisfy FDA manufacturing standards and the Drug Enforcement Administration’s shipment-by-shipment controls for Schedule I substances.
Dr. Priya NandakumarAug 14, 2026
Biopharmaceutical IndustryThe transaction centers on alvelestat, an investigational oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease. For Sentynl, the option structure creates a staged bet on a rare disease asset; for Mereo, it brings a commercial partner candidate and financing tied to getting the program to a new drug application submission.
Dr. Priya NandakumarAug 12, 2026
AI in Drug DiscoveryInvestor enthusiasm for companies such as Isomorphic Labs, Generate:Biomedicines and NewLimit is pushing biopharma to take machine learning more seriously across discovery and development. The clearest industry implication in the reporting is a shift from treating AI as a productivity tool to treating it as a way to identify failure earlier and allocate capital more selectively.
Dr. Priya NandakumarAug 12, 2026
Biopharmaceutical IndustryThe acquisition continues a deal-driven expansion in epilepsy for Jazz, whose neuroscience franchise is anchored by Epidiolex. Strategically, the transaction adds a potential first-in-class precision medicine in a niche indication where limited treatment options and a registrational path could support a differentiated rare disease play.
Dr. Priya NandakumarAug 11, 2026
Biopharmaceutical IndustryThe immediate catalyst is Definium’s Voyage readout in generalized anxiety disorder, with a second Phase 3 GAD study, Panorama, expected in September. At the same time, Compass has moved COMP360 into a partially filed rolling NDA for treatment-resistant depression, giving investors a more concrete marker for how psychedelic programs may transition from late-stage data into launch execution.
Dr. Priya NandakumarAug 10, 2026